I think LIB-3 is consequential to our amendment to clause 40. Again, this was made in consultation with both the generics and the innovative medicines in trying to come up with a compromise that is acceptable to the stakeholders. Again, we hope it's acceptable to the members of this committee so that we can pass the amendment.
